AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 JAN 16 - (NewsRx.com & NewsRx.net) -- Antex Biologics, Inc., (ANX) has begun a Phase I human clinical trial for the second component of its combination Activax vaccine to prevent travelers' diseases caused by the consumption of contaminated food and water.
The trial, to be carried out at the Johns Hopkins University Vaccine Testing Unit in Baltimore, Maryland, is designed to test the safety and immunogenicity of a vaccine against Shigella sonnei infection. The vaccine has been developed using the company's proprietary Nutriment Signal Transduction (NST) technology. There are currently no vaccines on the market for travelers' diseases, which are responsible for more than 3 million deaths a year worldwide.
Diseases caused by the consumption of contaminated food and water are the most prevalent illnesses afflicting travelers and are serious problems for military troops deployed overseas. Enteric bacteria, including Campylobacter jejuni, Shigella and Escherchia coli (ETEC), are the most common causes of these diseases, which can include gastritis, acute diarrhea, high fever, dehydration, severe dysentery and often ...